Full Year 2023 Investor Presentation

134 Investor presentation Full year 2023 North America Operations growth has accelerated DKK billion 1% 150 120 00 90 60 60 60 60 30 50 North America Operations reported sales growth per therapy area 3% 14% 67 20 61 21% 54% 137 91 0 2019 2020 2021 GLP-1 Insulin Other diabetes Obesity care Rare disease CER: Constant exchange rate 2022 Growth at CER NAO 2023

View entire presentation